Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
about
HIV and tuberculosis--science and implementation to turn the tide and reduce deathsIncidence of HIV-associated tuberculosis among individuals taking combination antiretroviral therapy: a systematic review and meta-analysisTB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysisA systematic review of published literature describing factors associated with tuberculosis recurrence in people living with HIV in AfricaRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirIncidence and Geographic Distribution of Extensively Drug-Resistant Tuberculosis in KwaZulu-Natal Province, South AfricaA Clinical Algorithm to Identify HIV Patients at High Risk for Incident Active Tuberculosis: A Prospective 5-Year Cohort StudyTuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapyThe rise and fall of tuberculosis in Malawi: associations with HIV infection and antiretroviral therapy.Factors Associated with Mortality of TB/HIV Co-infected Patients in Ethiopia.Sputum induction to aid diagnosis of smear-negative or sputum-scarce tuberculosis in adults in HIV-endemic settings.Comparison of trends in tuberculosis incidence among adults living with HIV and adults without HIV--Kenya, 1998-2012Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia.Systematic review of TST responses in people living with HIV in under-resourced settings: implications for isoniazid preventive therapy.HIV-associated tuberculosis: relationship between disease severity and the sensitivity of new sputum-based and urine-based diagnostic assays.Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trialPrevalent and incident tuberculosis are independent risk factors for mortality among patients accessing antiretroviral therapy in South Africa.Predicting the long-term impact of antiretroviral therapy scale-up on population incidence of tuberculosis.Tuberculosis among people living with HIV/AIDS in the German ClinSurv HIV Cohort: long-term incidence and risk factors.Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjectsThe predictive value of current haemoglobin levels for incident tuberculosis and/or mortality during long-term antiretroviral therapy in South Africa: a cohort studyDebunking the myths perpetuating low implementation of isoniazid preventive therapy amongst human immunodeficiency virus-infected persons.Incidence of tuberculosis and immunological profile of TB/HIV co-infected patients in Nigeria.What's next for tuberculosis control in sub-Saharan Africa?Enhancing the impact of antiretroviral scale-up on the HIV-associated tuberculosis epidemic in MalawiTuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapyTemporal trends in TB notification rates during ART scale-up in Cape Town: an ecological analysis.Tuberculosis Incidence and Risk Factors Among Human Immunodeficiency Virus (HIV)-Infected Adults Receiving Antiretroviral Therapy in a Large HIV Program in Nigeria.Tuberculosis Case Finding in HIV-Infected Pregnant Women in Kenya Reveals Poor Performance of Symptom Screening and Rapid Diagnostic TestsTuberculosis in Cape Town: An age-structured transmission model.HIV-1 and the immune response to TB.Tuberculosis after one year of combination antiretroviral therapy in Nigeria: a retrospective cohort studyVirologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, EthiopiaA Randomized, Controlled Safety, and Immunogenicity Trial of the M72/AS01 Candidate Tuberculosis Vaccine in HIV-Positive Indian Adults.Tuberculosis screening in patients with HIV: use of audit and feedback to improve quality of care in Ghana.Declining tuberculosis case notification rates with the scale-up of antiretroviral therapy in ZimbabweTemporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment serviceReducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.HIV-Related Medical Admissions to a South African District Hospital Remain Frequent Despite Effective Antiretroviral Therapy Scale-Up.Potential impact of the US President's Emergency Plan for AIDS relief on the tuberculosis/HIV coepidemic in selected Sub-Saharan African countries.
P2860
Q26824501-C58AFA70-166C-4753-89C9-DAA756735BF4Q27012753-6F711598-0AD5-443A-B983-640E551EB478Q28073480-AF73580B-011D-41D3-96B1-84BFAFED7385Q28387848-B625F000-EF92-4021-8436-D3AF3600F31EQ28533242-197D7891-3FD4-43AF-99D9-5B6B35F1ECB2Q28546261-12CF7448-8265-4835-9DA8-3085975A0168Q28547313-572EA8E4-2458-41B1-B649-195D56E76B0CQ28602123-CE13643F-4881-4125-86C4-884FE519CEB6Q30385976-A9491364-E8C1-4D55-9F99-00F52CF46CA5Q33596152-46926008-D527-4A07-AA59-F87FA94E9140Q33754205-3B1A4E34-3A39-4280-8DF6-9EF2C6C2888BQ33768889-1774BA49-679F-4AFD-978E-EE89672F02BAQ34020551-FA14BA69-AC46-4DEE-A20C-3C8EF5E12C13Q34499835-DF302386-E2EE-4918-B2C9-1C33178FD07EQ34509326-6E34B580-B497-426D-A19C-6C541BE075CCQ34519039-25D9FFC9-4682-4330-A721-9023B9908BABQ34589601-9A6DAC2A-636B-4BDF-B442-2AEE80DBEA6FQ34999621-2B0F49A3-14C9-4274-A5A2-792083AE84B8Q35124693-8982B6E5-9950-42EF-BE2E-E98A01B9A11BQ35154909-E1FFB0F3-CE34-415D-B8D9-2E69CBFD284CQ35544835-61F37FFE-0D68-4B77-9E36-6757ADA98A6EQ35567798-D3AF79ED-46BD-4DA5-8026-403F4DB46FD3Q35898590-D9C8F636-EA89-424A-A4BD-997B8C0F2540Q35944833-6B665F6A-E3E4-4469-958A-1DCBB00470E2Q35944889-0F146E82-902C-482D-9BD0-C1A0027563E9Q36078532-4C2FC558-9610-4488-8799-748ADACC907EQ36096194-DBABA2F1-B5BD-4547-B10F-DC3D2BA99CD4Q36302953-AC103796-66F4-4EAA-9C4C-5AB0EFA5614EQ36460138-2CC550BB-27B1-4063-8287-686FBF54D2B8Q36686287-4BACC96B-2E68-4352-A061-CBA125126CDAQ36815449-A82875EB-2A22-4103-B6DE-DE72590FF17EQ36842083-8F4F9D08-8A52-4490-BC98-6E16819F7003Q37033512-F0D26641-5334-492E-A14A-4A4D82BBF207Q37204894-FB1D8AC2-4B76-4F37-BBD9-EE6EED76CA61Q37212402-7AB7C12B-03CB-42F7-B598-83A9A1495D89Q37279224-AD99910E-DB68-4C07-BACD-F4158901A742Q37284765-15E003FE-4BE1-431F-BDBC-6D2E1C6F2C63Q37285167-4FE9E8EB-7B0D-482E-AB9E-61D06A92C41BQ37328357-3228C184-09EA-4748-88A6-D83993595B3FQ37332200-E342641A-6944-4330-B2FF-AD5B0E157FFA
P2860
Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Tuberculosis incidence rates d ...... n with rates in the community.
@ast
Tuberculosis incidence rates d ...... n with rates in the community.
@en
Tuberculosis incidence rates d ...... n with rates in the community.
@nl
type
label
Tuberculosis incidence rates d ...... n with rates in the community.
@ast
Tuberculosis incidence rates d ...... n with rates in the community.
@en
Tuberculosis incidence rates d ...... n with rates in the community.
@nl
prefLabel
Tuberculosis incidence rates d ...... n with rates in the community.
@ast
Tuberculosis incidence rates d ...... n with rates in the community.
@en
Tuberculosis incidence rates d ...... n with rates in the community.
@nl
P2860
P50
P921
P1433
P1476
Tuberculosis incidence rates d ...... n with rates in the community.
@en
P2093
Ankur Gupta
P2860
P304
P356
10.1371/JOURNAL.PONE.0034156
P407
P577
2012-03-30T00:00:00Z